Table I.
Patients’ characteristics
| Variable | N = 82 | |
|---|---|---|
| Baseline characteristics | ||
| Age [year] | 4.6 (3.3, 7.0), 1.0-13.2 | |
| Age category | 1-6 years > 6 years |
54 (65.9%) 28 (34.1%) |
| Gender | Male Female |
53 (64.6%) 29 (35.4%) |
| Risk group | Standard Intermedia High |
28 (34.1%) 39 (47.6%) 15 (18.3%) |
| Immunology | T cell Common B cell Pre-B cell Early pre-B cell |
6 (7.3%) 59 (72.0%) 8 (9.8%) 9 (11.0%) |
| Pathologic types | L1 L1/L2 L2 L3 |
52 (63.4%) 16 (19.5%) 13 (15.9%) 1 (1.2%) |
| CNS involvement | – + |
78 (95.1%) 4 (4.9%) |
| Testicular involvement | – + |
79 (96.3%) 3 (3.7%) |
| TEL/AML1 | – + |
70 (85.4%) 12 (14.6%) |
| E2A/PBX1 | – + |
81 (98.8%) 1 (1.2%) |
| BCR/ABL | – + |
81 (98.8%) 1 (1.2%) |
| WBC (109/l) | < 20 20-100 > 100 |
54 (65.9%) 22 (26.8%) 6 (7.3%) |
| Post-treatment characteristics | ||
| D8 peripheral leukemic cells [/μl] | ≤ 1000 > 1000 |
78 (95.1%) 4 (4.9%) |
| D15 bone marrow leukemic cells [%] | None < 5 5-25 > 25 |
41 (50.0%) 23 (28.0%) 10 (12.2%) 8 (9.8%) |
| D33 bone marrow leukemic cells [%] | None < 5 5-25 > 25 |
53 (64.6%) 27 (32.9%) 1 (1.2%) 1 (1.2%) |
Data are presented as count and percentage except for age, which is presented as median, inter-quartile range, and full range